论文部分内容阅读
非洛地平是血管选择性二氢吡啶类钙离子拮抗剂,以前应用的是需日服2次的普通片剂,最近,每日服用1次的缓释制剂(Extended Release,ER)已在临床应用,得到不少经验。非洛地平ER在患有原发性高血压的病人中进行了研究。单独使用该制剂治疗轻度到中度原发性高血压,在降低血压方面与其它钙离子拮抗剂、β-受体阻断剂、利尿剂、ACE抑制剂的效果相似,而且非洛地平ER在某些方面优于同剂量的普通片剂。它也可与控释的美托洛尔或依拉普利联用治疗轻度到中度原发性高血压。在有安慰剂对照的研究中,服用β受体阻滞剂和(或)利尿剂未能控制的重度原发性高血压患者,加用非洛地平ER是有效的。在常用剂量下既优于硝苯啶缓释制剂又优于尼群地平缓释制剂。
Felodipine is a vaso-selective dihydropyridine calcium antagonist. Previously, conventional tablets were applied twice daily. Recently, Extended Release (ER), taken once daily, has been used clinically Application, get a lot of experience. Felodipine ER has been studied in patients with essential hypertension. The agent used alone in the treatment of mild to moderate essential hypertension has the similar effect as other calcium ion antagonists, β-blockers, diuretics, ACE inhibitors in lowering blood pressure, and the effect of felodipine ER In some ways superior to the same dose of common tablets. It can also be used with metoprolol or controlled-release metoprolol in the treatment of mild to moderate essential hypertension. In a placebo-controlled study, felodipine ER was effective in patients with severe essential hypertension who were taking beta-blockers and / or diuretics uncontrollable. It is superior to nifedipine sustained-release preparation and nitrendipine sustained-release preparation at the usual dosage.